BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 27, 2025
Home » Authors » Kim Coghill

Articles by Kim Coghill

XOMA's Acne Gel Stumbles In Phase II; Stock Falls 35 Percent

Aug. 18, 2004
By Kim Coghill

XOMA's Acne Gel Stumbles In Phase II; Stock Falls 35 Percent

Aug. 18, 2004
By Kim Coghill

Palatin Partners With King On Sexual Dysfunction Candidate

Aug. 16, 2004
By Kim Coghill
Palatin Technologies Inc. could make more than $250 million via a strategic alliance with King Pharmaceuticals Inc. for the development and commercialization of Palatin's male and female sexual dysfunction candidate, PT-141. (BioWorld Today)
Read More

Palatin Partners With King On Sexual Dysfunction Candidate

Aug. 16, 2004
By Kim Coghill
Palatin Technologies Inc. could make more than $250 million via a strategic alliance with King Pharmaceuticals Inc. for the development and commercialization of Palatin's male and female sexual dysfunction candidate, PT-141. (BioWorld Today)
Read More

Vicuron Plans NDA Filing After Dalbavancin Phase III Analysis

Aug. 13, 2004
By Kim Coghill
Vicuron Pharmaceuticals Inc.'s stock soared 21.9 percent Thursday after the firm said it would seek regulatory approval later this year on favorable data from a Phase III program of once-weekly dalbavancin in skin and soft-tissue infections caused by Gram-positive bacteria. (BioWorld Today)
Read More

Vicuron Plans NDA Filing After Dalbavancin Phase III Analysis

Aug. 13, 2004
By Kim Coghill
Vicuron Pharmaceuticals Inc.'s stock soared 21.9 percent Thursday after the firm said it would seek regulatory approval later this year on favorable data from a Phase III program of once-weekly dalbavancin in skin and soft-tissue infections caused by Gram-positive bacteria. (BioWorld Today)
Read More

Oscient Encouraged Despite Missed Endpoint In Phase II

Aug. 12, 2004
By Kim Coghill
While Oscient Pharmaceuticals Corp. missed its primary endpoint in a Phase II trial of Ramoplanin for the treatment of Clostridium difficile-associated diarrhea, the firm believes the trial's preliminary data are encouraging, and hopes to move into Phase III studies by the end of the year. (BioWorld Today)
Read More

Oscient Encouraged Despite Missed Endpoint In Phase II

Aug. 12, 2004
By Kim Coghill
While Oscient Pharmaceuticals Corp. missed its primary endpoint in a Phase II trial of Ramoplanin for the treatment of Clostridium difficile-associated diarrhea, the firm believes the trial's preliminary data are encouraging, and hopes to move into Phase III studies by the end of the year. (BioWorld Today)
Read More

Bioenvision Begins Pivotal Trial Of Clofarabine For AML In Europe

Aug. 11, 2004
By Kim Coghill

QLT Enlists Array To Assist With Work On Cancer Targets

Aug. 11, 2004
By Kim Coghill
Previous 1 2 3 4 5 6 7 8 9 10 … 142 143 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 25, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing